| HORIZON | TRADES | WIN RATE | INSIDER RETURN | SPY RETURN | MEAN EXCESS | MEDIAN EXCESS | T-STAT |
|---|---|---|---|---|---|---|---|
| 7d | 5 | +40.00% | +8.94% | +0.38% | +8.56% | +12.47% | — |
| 14d | 5 | +20.00% | +15.17% | +0.39% | +14.78% | +10.86% | — |
| 30d | 5 | +60.00% | -7.05% | +0.68% | -7.73% | -20.55% | — |
| 60d | 5 | +60.00% | -9.22% | +1.41% | -10.63% | -21.31% | — |
| 90d | 5 | +60.00% | -5.83% | +0.06% | -5.89% | -34.14% | — |
| 180d | 5 | +80.00% | -7.71% | +3.56% | -11.26% | -25.68% | — |
| 1y | 5(2 pending) | +33.33% | +14.60% | +18.12% | -3.51% | -8.21% | — |
| 2y | 5(5 pending) | — | — | — | — | — | — |
| COMPANY | TYPE | SHARES | PRICE | VALUE | HELD AFTER | TRADE DATE | FILED | DETAILS |
|---|---|---|---|---|---|---|---|---|
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 17,250 | — | — | 69,527 | Mar 1, 2026 | Mar 3, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE VP, Chief Accounting Officer | 2,989 | $9.21 | $27.5K | 52,277 | Jan 5, 2026 | Jan 7, 2026 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE VP, Chief Accounting Officer | 1,871 | $17.38 | $32.5K | 55,266 | Oct 1, 2025 | Oct 3, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE VP, Chief Accounting Officer | 2,503 | $9.95 | $24.9K | 57,137 | Jul 2, 2025 | Jul 3, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 14,000 | — | — | 59,640 | Mar 1, 2025 | Mar 4, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE VP, Chief Accounting Officer | 1,372 | $12.18 | $16.7K | 45,640 | Jan 3, 2025 | Jan 7, 2025 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | SALE VP, Chief Accounting Officer | 2,012 | $19.01 | $38.2K | 47,012 | Oct 2, 2024 | Oct 4, 2024 ↗ | View → |
| NTLA INTELLIA THERAPEUTICS, INC. | PURCHASEGRANT Stock grant | 17,801 | — | — | 49,024 | Jul 1, 2024 | Jul 3, 2024 ↗ | View → |